Abstract

This study analyzes to elucidate the efficacy and safety of salmeterol/fluticasone propionate plus tiotropium bromide in the treatment of chronic obstructive pulmonary disease. 120 chronic obstructive pulmonary disease patients admitted between April 2019 to April 2022 were selected and were divided into research group (n=62) and control group (n=58). The research group received salmeterol/fluticasone propionate+tiotropium bromide therapy while the control group received tiotropium bromide. The efficacy, safety (headache, constipation, palpitation, and upper respiratory tract infection), pulmonary function, forced expiratory volume in 1 s/forced vital capacity ratio, serum inflammatory markers like c-reactive protein, interleukin-8, tumor necrosis factor-alpha and quality of life according to Saint George’s respiratory questionnaire were comparatively evaluated. The overall response rate was found to be markedly higher in the research group than the control group. A similar incidence of adverse reactions was determined in both the groups. In addition, the research groups showed higher post-interventional forced expiratory volume in 1 s/forced vital capacity, forced expiratory volume in 1 s/forced vital capacity ratio and Saint George’s respiratory questionnaire than the control group, as well as statistically lower c-reactive protein, interleukin-8 and tumor necrosis factor-alpha levels. The above results demonstrate excellent efficacy of salmeterol/fluticasone propionate plus tiotropium bromide for the treatment of chronic obstructive pulmonary disease, with a safety profile comparable to that of tiotropium bromide monotherapy with better effects improving pulmonary function, inhibiting serum inflammatory markers, and enhancing patients’ quality of life.